Efficacy of JAK Inhibitors versus DMARDs in the Treatment of Polymyalgia Rheumatica in China

References

• Crowson CS, Matteson EL, Myasoedova E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(3):633–639. doi:10.1002/art.30155
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Matteson EL, Castaneda S. Polymyalgia rheumatica. Lancet. 2017;390(10103):1700–1712. doi:10.1016/S0140-6736(17)31825-1
   PubMed Web of Science ®Google Scholar
• Camellino D, Giusti A, Girasole G, Bianchi G, Dejaco C. Pathogenesis, diagnosis and management of polymyalgia rheumatica. Drugs Aging. 2019;36(11):1015–1026. doi:10.1007/s40266-019-00705-5
   PubMed Web of Science ®Google Scholar
• Floris A, Piga M, Chessa E, et al. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis. Clin Rheumatol. 2021;41(1):19–31. doi:10.1007/s10067-021-05819-z
   PubMed Web of Science ®Google Scholar
• Aoki D, Kajiwara N, Irishio K, et al. Withdrawal of glucocorticoid therapy is difficult in women with polymyalgia rheumatica: an observational study. Int J Gen Med. 2021;14:6417–6422. doi:10.2147/IJGM.S322111
   PubMed Web of Science ®Google Scholar
• Dejaco C, Singh YP, Perel P, et al.; European League Against R and American College of R. 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799–1807. doi:10.1136/annrheumdis-2015-207492
   PubMed Web of Science ®Google Scholar
• Ughi N, Sebastiani GD, Gerli R, et al. The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica. Reumatismo. 2020;72(1):1–15. doi:10.4081/reumatismo.2020.1268
   PubMed Web of Science ®Google Scholar
• Devauchelle-Pensec V, Berthelot JM, Cornec D, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75(8):1506–1510. doi:10.1136/annrheumdis-2015-208742
   PubMed Web of Science ®Google Scholar
• Lally L, Forbess L, Hatzis C, Spiera R. Brief report: a prospective open-label Phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheumatol. 2016;68(10):2550–2554. doi:10.1002/art.39740
   PubMed Web of Science ®Google Scholar
• Akiyama M, Kaneko Y, Takeuchi T. Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review. Semin Arthritis Rheum. 2020;50(3):521–525. doi:10.1016/j.semarthrit.2019.12.005
   PubMed Web of Science ®Google Scholar
• Chino K, Kondo T, Sakai R, et al. Tocilizumab monotherapy for polymyalgia rheumatica: a prospective, single-center, open-label study. Int J Rheum Dis. 2019;22(12):2151–2157. doi:10.1111/1756-185X.13723
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Cimmino MA, Maradit-Kremers H, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484–492. doi:10.1136/annrheumdis-2011-200329
   PubMed Web of Science ®Google Scholar
• Horai Y, Otsuka M, Kawahara C, et al. Clinical analysis of gender and pre-existing diabetes mellitus in patients with polymyalgia rheumatica: a retrospective study in a Japanese population. Mod Rheumatol. 2023;33(1):182–186. doi:10.1093/mr/roac012
   PubMed Web of Science ®Google Scholar
• Carvajal Alegria G, Boukhlal S, Cornec D, Devauchelle-Pensec V. The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle. Autoimmun Rev. 2020;19(11):102670. doi:10.1016/j.autrev.2020.102670
   PubMed Web of Science ®Google Scholar
• Castaneda S, Garcia-Castaneda N, Prieto-Pena D, et al. Treatment of polymyalgia rheumatica. Biochem Pharmacol. 2019;165:221–229. doi:10.1016/j.bcp.2019.03.027
   PubMed Web of Science ®Google Scholar
• Camellino D, Matteson EL, Buttgereit F, Dejaco C. Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. Nat Rev Rheumatol. 2020;16(9):481–495. doi:10.1038/s41584-020-0458-5
   PubMed Web of Science ®Google Scholar
• McLornan DP, Pope JE, Gotlib J, Harrison CN. Current and future status of JAK inhibitors. Lancet. 2021;398(10302):803–816. doi:10.1016/S0140-6736(21)00438-4
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Pina T, Prieto-Pena D, Calderon-Goercke M, Gualillo O, Castaneda S. Treatment of giant cell arteritis. Biochem Pharmacol. 2019;165:230–239. doi:10.1016/j.bcp.2019.04.027
   PubMed Web of Science ®Google Scholar
• Gazitt T, Zisman D, Gardner G. Polymyalgia rheumatica: a common disease in seniors. Curr Rheumatol Rep. 2020;22(8):40. doi:10.1007/s11926-020-00919-2
   PubMed Web of Science ®Google Scholar
• Zhang L, Li J, Yin H, et al. Efficacy and safety of tofacitinib in patients with polymyalgia rheumatica: a Phase 2 study. Ann Rheum Dis. 2023;82(5):722–724. doi:10.1136/ard-2022-223562
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243. doi:10.1038/nrrheum.2017.23
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O’Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843–1847. doi:10.1136/annrheumdis-2016-209131
   PubMed Web of Science ®Google Scholar